Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Retinal Step Therapy Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentZing HealthPolicy 6936-D

    Medicare Part B Step Therapy Retinal Disorders

    Customize your policy alerts

    Sign up for zing_health Policy 6936-D alerts

    Get alerted when Policy 6936-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage of preferred and non-preferred products used for retinal disorders under Zing Health. Non-preferred products require prior authorization and a clinical exception based on prior treatment, inadequate response, intolerable adverse events, or specified diagnoses.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Retinal Disorders
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation supporting prior treatment, inadequate response, intolerable adverse events, or the applicable diagnosis-specific exception for non-preferred products.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Part BApplicable benefit
    1Primary preferred product
    4Secondary preferred products
    6Non-preferred products

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    365 days
    Prior-treatment lookback
    AB firstPlan design

    Non-Preferred Product Exceptions

    General, Eylea, Eylea HD, and Lucentis exceptions

    Coverage for a non-preferred product is provided when any of the following criteria are met.

    Qualifying exception

    • Prior use: The member has received treatment with the requested non-preferred product in the past 365 days.Past 365 days
    • Eylea or Pavblu exception

      • Requested product: The requested product is Eylea or Pavblu.
      • Qualifying condition

        • Diagnosis: The member has a diagnosis of retinopathy of prematurity.
        • Avastin failure or intolerance: The member has had a documented inadequate response or intolerable adverse event with Avastin.Documented inadequate response or intolerable adverse event
    • Eylea HD or Lucentis exception

      • Requested product: The requested product is Eylea HD or Lucentis.
      • Avastin failure or intolerance: The member has had a documented inadequate response or intolerable adverse event with Avastin.Documented inadequate response or intolerable adverse event

    Beovu, Vabysmo, Byooviz, and Cimerli exceptions

    Coverage for Beovu or Vabysmo requires both of the following.

    Beovu or Vabysmo exception

    • Requested product: The requested product is Beovu or Vabysmo.
    • Required preferred-product history

      • Avastin failure or intolerance: The member has had a documented inadequate response or intolerable adverse event with Avastin.Documented inadequate response or intolerable adverse event
      • Secondary preferred-product failure or intolerance: The member has had a documented inadequate response or intolerable adverse event with any of the secondary preferred products: Eylea, Eylea HD, Lucentis, or Pavblu.Any listed secondary preferred product

    Byooviz, Cimerli, and Susvimo exceptions

    For Byooviz or Cimerli when the diagnosis is other than myopic choroidal neovascularization, both of the following are required.

    Qualifying exception

    • Byooviz or Cimerli for mCNV

      • Requested product: The requested product is Byooviz or Cimerli.
      • Diagnosis: The member has a diagnosis of myopic choroidal neovascularization (mCNV).
      • Required treatment history

        • Avastin failure or intolerance: The member has had a documented inadequate response or intolerable adverse event with Avastin.Documented inadequate response or intolerable adverse event

    Prior Treatment Lookback

    Prior Treatment Requirement
    Qualifying prior treatmentTreatment with the requested non-preferred product
    Lookback periodWithin the past 365 days
    Coverage effectPrior use may qualify for coverage instead of meeting product-specific exception criteria

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization and Clinical Exception Required

    Submit a clinical prior authorization request for a non-preferred retinal disorder product. Coverage is available through an exception review when clinical circumstances exclude use of the preferred product; this step-therapy program applies to members who are new to treatment with a non-preferred product.

    • Document the requested product, diagnosis, relevant prior treatment history, and the clinical rationale for requesting a non-preferred product.
    • Medications identified as preferred may still require clinical prior authorization review.
    • Apply this requirement in addition to any applicable NCD, LCD, or Medicare Part B utilization-management program.
    Step Therapy

    Step Therapy Applies to New Non-Preferred Therapy

    For members new to non-preferred therapy, Medicare Part B retinal disorder step therapy requires an applicable exception before coverage of the requested non-preferred product. A qualifying exception may be based on treatment with the requested product during the previous 365 days or on the product-specific criteria below.

    Policy Scope and Preferred Products

    This policy addresses retinal disorder drug treatment under Medicare Part B and uses an advanced-biosimilars-first design. Avastin (bevacizumab) is the primary preferred product. Eylea, Eylea HD, Lucentis, and Pavblu are identified as secondary preferred products, while other listed products are non-preferred and may require a clinical exception through prior authorization.

    Utilization Management Terms

    Step Therapy
    DefinitionA utilization management program requiring use of preferred products before coverage of a non-preferred product
    Preferred-product sequenceUse Avastin as the primary preferred product and, when required, demonstrate failure or intolerance to specified secondary preferred products
    ApplicabilityApplies to members who are new to treatment with a non-preferred product for the first time
    Additional requirementsApplied in addition to any applicable National Coverage Determination, Local Coverage Determination, or Medicare Part B utilization management program
    Clinical Exception
    DefinitionA review pathway for coverage of a non-preferred product when specified clinical circumstances exclude or make inadequate the use of preferred products

    Initial Non-Preferred Therapy

    Initial non-preferred therapy exception

    Coverage for a non-preferred product is provided when any applicable exception is met.

    Applicable exception

    • Prior use: The member used the requested non-preferred product within the past 365 days.Past 365 days
    • Product-specific exception: The requested product meets its applicable diagnosis-specific and preferred-product failure or intolerance criteria.Product-specific diagnosis and treatment-history requirements

      Detailed product criteria are stated in the coverage criteria.

    Required Product Sequence

    StepPreferred productCoverage requirement
    1AvastinUse Avastin as the primary preferred product. When required by the requested product, document an inadequate response or intolerable adverse event with Avastin.
    Requested product(s)Applicable exception criteria
    Eylea or PavbluThe member received treatment with the requested product within the past 365 days; or the member has retinopathy of prematurity; or the member has a documented inadequate response or intolerable adverse event with Avastin.
    Eylea HD or LucentisThe member received treatment with the requested product within the past 365 days; or the member has a documented inadequate response or intolerable adverse event with Avastin.
    Beovu or VabysmoThe member received treatment with the requested product within the past 365 days; or the member has a documented inadequate response or intolerable adverse event with Avastin and a documented inadequate response or intolerable adverse event with any of Eylea, Eylea HD, Lucentis, or Pavblu.
    Byooviz or CimerliThe member received treatment with the requested product within the past 365 days; or, for myopic choroidal neovascularization, the member has a documented inadequate response or intolerable adverse event with Avastin and a documented intolerable adverse event to Lucentis that was not an expected adverse event attributed to the active ingredient; or, for another diagnosis, the member has a documented inadequate response or intolerable adverse event with Avastin and either the same Lucentis exception or a documented inadequate response or intolerable adverse event with Eylea, Eylea HD, or Pavblu.
    SusvimoThe member received treatment with the requested product within the past 365 days; or the member has a documented inadequate response or intolerable adverse event with Avastin and either a documented intolerable adverse event to Lucentis that was not an expected adverse event attributed to the active ingredient or a documented inadequate response or intolerable adverse event with Eylea, Eylea HD, or Pavblu.

    Product-Specific Biosimilar Notes

    Billing Rule

    Pavblu status and exception review

    Pavblu (aflibercept-ayyh) is listed as a secondary preferred product and also appears in the non-preferred product list. A non-preferred Pavblu request follows the clinical exception criteria.

    • A Pavblu request may qualify when the member has retinopathy of prematurity.
    • Alternatively, document an inadequate response or intolerable adverse event with Avastin.
    • Prior treatment with Pavblu within the past 365 days may also satisfy the general exception.
    Billing Rule

    Byooviz requires preferred-product history

    Byooviz (ranibizumab-nuna) is non-preferred. Coverage requires the specified Avastin and Lucentis or other secondary preferred-product failure or intolerance criteria, depending on the diagnosis.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Retinal Disorders
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation supporting prior treatment, inadequate response, intolerable adverse events, or the applicable diagnosis-specific exception for non-preferred products.
    SourceLink
    On This Page
    Non-Preferred Product ExceptionsPrior Treatment LookbackAuthorization and Documentation RequirementsPolicy Scope and Preferred ProductsUtilization Management TermsInitial Non-Preferred TherapyRequired Product SequenceProduct-Specific Biosimilar Notes
  1. Lucentis adverse-event exception: The member has had a documented intolerable adverse event to Lucentis, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.Documented intolerable adverse event not attributed to the active ingredient
  2. Byooviz or Cimerli for diagnosis other than mCNV

    • Requested product: The requested product is Byooviz or Cimerli.
    • Diagnosis: The member has a diagnosis other than myopic choroidal neovascularization (mCNV).
    • Required treatment history

      • Avastin failure or intolerance: The member has had a documented inadequate response or intolerable adverse event with Avastin.Documented inadequate response or intolerable adverse event
      • Secondary preferred-product exception

        • Lucentis adverse-event exception: The member has had a documented intolerable adverse event to Lucentis, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.Documented intolerable adverse event not attributed to the active ingredient
        • Eylea, Eylea HD, or Pavblu failure or intolerance: The member has had a documented inadequate response or intolerable adverse event with any of the secondary preferred products: Eylea, Eylea HD, or Pavblu.Any listed secondary preferred product
  3. Susvimo exception

    • Requested product: The requested product is Susvimo.
    • Required treatment history

      • Avastin failure or intolerance: The member has had a documented inadequate response or intolerable adverse event with Avastin.Documented inadequate response or intolerable adverse event
      • Secondary preferred-product exception

        • Lucentis adverse-event exception: The member has had a documented intolerable adverse event to Lucentis, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.Documented intolerable adverse event not attributed to the active ingredient
        • Eylea, Eylea HD, or Pavblu failure or intolerance: The member has had a documented inadequate response or intolerable adverse event with any of the secondary preferred products: Eylea, Eylea HD, or Pavblu.Any listed secondary preferred product
  4. Prior use alternative: The member has received treatment with the requested non-preferred product in the past 365 days.Past 365 days
    • Eylea or Pavblu: diagnosis of retinopathy of prematurity, or documented inadequate response or intolerable adverse event with Avastin.
    • Eylea HD or Lucentis: documented inadequate response or intolerable adverse event with Avastin.
    • Beovu or Vabysmo: documented inadequate response or intolerable adverse event with Avastin and with a secondary preferred product—Eylea, Eylea HD, Lucentis, or Pavblu.
    • Byooviz or Cimerli: documented inadequate response or intolerable adverse event with Avastin plus the applicable Lucentis, Eylea, Eylea HD, or Pavblu history; mCNV cases also require the specified Lucentis intolerance to be unrelated to an expected active-ingredient adverse effect.
    • Susvimo: documented inadequate response or intolerable adverse event with Avastin plus the specified Lucentis intolerance or inadequate response/intolerance to Eylea, Eylea HD, or Pavblu.
    Documentation Required

    Clinical Exception Documentation

    Include sufficient clinical exception documentation for the requested non-preferred product. The record must establish the member’s diagnosis, prior treatment with required preferred products or the requested product, and the documented response or intolerance supporting the exception.

    • Diagnosis and, when applicable, whether the condition is retinopathy of prematurity, myopic choroidal neovascularization (mCNV), or another diagnosis.
    • Prior treatment history, including treatment with the requested product within the past 365 days when applicable.
    • For each required preferred product, document inadequate response or an intolerable adverse event; identify the product and provide the relevant clinical details.
    • For Lucentis intolerance requirements, document that the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.
    Denial Risk

    Non-Preferred Criteria Not Met

    A non-preferred product may be denied when the required treatment lookback or product-specific clinical exception criteria are not established. The request must show either treatment with the requested product in the previous 365 days or all applicable diagnosis, prior-treatment, and response or intolerance requirements.

    • No documented treatment with the requested non-preferred product during the preceding 365 days when relying on the lookback pathway.
    • Required diagnosis is absent or does not match the applicable product criterion.
    • Required inadequate response or intolerable adverse event with preferred therapy is not documented.
    • Required combination of prior-treatment and exception criteria is incomplete, including the additional preferred-product history required for Beovu, Vabysmo, Byooviz, Cimerli, or Susvimo.
    Denial Risk

    Required Preferred-Product History

    Requests are at risk for denial when the required preferred-product history is missing or does not demonstrate inadequate response or intolerance. Document the applicable sequence of Avastin and secondary preferred-product trials, including the product-specific requirements for the requested therapy.

    • Avastin is the primary preferred product; secondary preferred products include Eylea, Eylea HD, Lucentis, and Pavblu.
    • Document inadequate response or intolerance to Avastin when required.
    • For products requiring secondary preferred-product history, identify the secondary product or products tried and document inadequate response or intolerance as specified.
    • For Lucentis adverse-event exceptions, document that the event was not an expected active-ingredient adverse effect; otherwise, the exception may not qualify.
    Qualifying circumstancesPrior use, documented inadequate response, intolerable adverse events, or specified diagnosis and product-specific requirements
    Review outcomeCoverage is provided when the applicable clinical exception criteria are met
    Submission requirementThe provider must submit documentation supporting the applicable exception
    Inadequate Response or Intolerable Adverse Event
    Inadequate responseTreatment did not adequately control the condition
    Intolerable adverse eventA harmful or unacceptable reaction to treatment that supports an exception when documented
    Documentation standardThe response or reaction must be documented for the required preferred product history
    Lucentis-specific requirementFor applicable exceptions, a Lucentis adverse event must not be an expected adverse event attributed to the active ingredient as described in the prescribing information
  5. For myopic choroidal neovascularization, document inadequate response or intolerance to Avastin and an intolerable Lucentis adverse event that was not an expected active-ingredient reaction.
  6. For a diagnosis other than myopic choroidal neovascularization, document inadequate response or intolerance to Avastin and either the qualifying Lucentis adverse event or inadequate response or intolerance to Eylea, Eylea HD, or Pavblu.
  7. Billing Rule

    Cimerli requires preferred-product history

    Cimerli (ranibizumab-eqrn) is non-preferred. Coverage requires the specified Avastin and Lucentis or other secondary preferred-product failure or intolerance criteria, depending on the diagnosis.

    • For myopic choroidal neovascularization, document inadequate response or intolerance to Avastin and an intolerable Lucentis adverse event that was not an expected active-ingredient reaction.
    • For a diagnosis other than myopic choroidal neovascularization, document inadequate response or intolerance to Avastin and either the qualifying Lucentis adverse event or inadequate response or intolerance to Eylea, Eylea HD, or Pavblu.